[go: up one dir, main page]

PE20080612A1 - Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia - Google Patents

Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia

Info

Publication number
PE20080612A1
PE20080612A1 PE2007001140A PE2007001140A PE20080612A1 PE 20080612 A1 PE20080612 A1 PE 20080612A1 PE 2007001140 A PE2007001140 A PE 2007001140A PE 2007001140 A PE2007001140 A PE 2007001140A PE 20080612 A1 PE20080612 A1 PE 20080612A1
Authority
PE
Peru
Prior art keywords
therapy
hepatitis
hcv
treatment
pharmaceutical compositions
Prior art date
Application number
PE2007001140A
Other languages
English (en)
Inventor
Anita Y M Howe
Stephen A Villano
Original Assignee
Viropharma Inc
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viropharma Inc, Wyeth Corp filed Critical Viropharma Inc
Publication of PE20080612A1 publication Critical patent/PE20080612A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA CANTIDAD ANTI-HCV DE METILAMIDA DEL ACIDO 5-CICLOPROPIL-2-(4-FLUORO-FENIL)-6-[(2-HIDROXI-ETIL)-METANSULFONIL-AMINO]-BENZOFURAN-3-CARBOXILICO; B) UNA CANTIDAD EFECTIVA ANTI-HCVDE INTERFERON-ALFA-2B-PEGILADO. COMPRENDE ADEMAS UN AGENTE BIOLOGICAMENTE ACTIVO SELECCIONADO DE RIBAVIRINA, INHIBIDORES DE PROTEASA, COMPUESTOS DE ARN INTERFERENTE PEQUENO, INMUNOGLOBULINAS, ENTRE OTROS. DICHA COMPOSICION FARMACEUTICA ES UTIL EN LA INHIBICION DE LA REPLICACION VIRAL EN HCV
PE2007001140A 2006-08-25 2007-08-22 Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia PE20080612A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84008506P 2006-08-25 2006-08-25

Publications (1)

Publication Number Publication Date
PE20080612A1 true PE20080612A1 (es) 2008-07-23

Family

ID=39107638

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001140A PE20080612A1 (es) 2006-08-25 2007-08-22 Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia

Country Status (7)

Country Link
US (1) US20080075695A1 (es)
AR (1) AR062453A1 (es)
CL (1) CL2007002490A1 (es)
PA (1) PA8744101A1 (es)
PE (1) PE20080612A1 (es)
TW (1) TW200815384A (es)
WO (1) WO2008024843A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024763A2 (en) * 2006-08-25 2008-02-28 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
US8048887B2 (en) * 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
RS54368B1 (sr) 2010-03-31 2016-04-28 Gilead Pharmasset Llc Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA201490837A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
JP2020533337A (ja) 2017-09-12 2020-11-19 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． 重水素原子置換インドールホルムアミド誘導体、その調製方法、およびその医療用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050065661A (ko) * 2002-11-01 2005-06-29 비로파마 인코포레이티드 벤조푸란 화합물, 조성물 및 ｃ형 간염 바이러스 감염 및관련 질병의 치료 및 예방 방법
PL1835951T3 (pl) * 2004-12-20 2011-11-30 Codman & Shurtleff Inhibitor HCV do stosowania w leczeniu zapalenia wątroby typu C
EP1853317A2 (en) * 2005-02-09 2007-11-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections

Also Published As

Publication number Publication date
TW200815384A (en) 2008-04-01
WO2008024843A2 (en) 2008-02-28
US20080075695A1 (en) 2008-03-27
AR062453A1 (es) 2008-11-12
WO2008024843A3 (en) 2008-10-30
PA8744101A1 (es) 2009-04-23
CL2007002490A1 (es) 2008-03-07

Similar Documents

Publication Publication Date Title
PE20080612A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
EA200601467A1 (ru) Макроциклические соединения в качестве ингибиторов вирусной репликации
EA200900297A1 (ru) Ингибиторы вируса гепатита с
PE20090228A1 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
BRPI0822335A2 (pt) inibidores do vírus da hepatite c
ECSP12011944A (es) Ácidos carboxílicos macrocíclicos y acilsulfonamidas como inhibidores de replicación del hcv
EA201100927A1 (ru) Циклические аналоги 4-амино-4-оксобутаноил-пептидов, ингибиторы репликации вирусов
EA200900298A1 (ru) Ингибиторы вируса гепатита с
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
BR112012024923A2 (pt) "fosforamidatos de nucleosídeo, composição, comprimido, e seus usos"
WO2005123087A3 (en) C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
JP2012512169A5 (es)
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
MY176918A (en) N- [ (2 ' r) -2' -deoxy-2' -fluoro-2' -methyl-p-phenyl-5' -uridylyl] - l-alanine 1-methylethyl ester and process for its production
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
NO20062428L (no) Kombinasjoner for HCV-behandling
PE20150202A1 (es) Compuestos antivirales
CU20100203A7 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de la hepatitis c
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
PE20131397A1 (es) Terapia de combinacion para tratar infeccion por hcv
PE20091164A1 (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
EA201200650A1 (ru) Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин

Legal Events

Date Code Title Description
FD Application declared void or lapsed